Cleveland Clinic is a nonprofit, multispecialty academic medical center integrating outpatient and hospital care with research and education for better patient outcomes and experience. More than 4,500 staff physicians and researchers provide services through 20 patient-centered institutes. Cleveland Clinic is a 6,500-bed healthcare system with a main campus in Cleveland, 22 hospitals and over 220 outpatient locations. The health system includes five hospitals in Southeast Florida with more than 1,000 beds, a medical center for brain health in Las Vegas, a sports and executive health center in Toronto, and a 364-bed hospital in Abu Dhabi. Cleveland Clinic London, a 184-bed hospital, opened in March 2022. Cleveland Clinic is currently ranked as one of the nation’s top hospitals by U.S. News & World Report.
Effect of HbA1c Elevation, Glycemic Control Following Mechanical Thrombectomy: David Baker, DOMarch 15th 2023
The vascular neurologist at Cleveland Clinic provided an overview of a study that assessed the extent HbA1c impacts the relationship between mechanical thrombectomy and poor outcomes. [WATCH TIME: 3 minutes]
Ganaxolone’s Significant Effect on CDKL5 Deficiency Disorder: Elia Pestana-Knight, MDMarch 1st 2023
The pediatric epileptologist at Cleveland Clinic provided insight on her presentation at the 2022 AAN Annual Meeting that evaluated ganaxolone in phase 3 study of patients with CDKL5 deficiency disorder. [WATCH TIME: 4 minutes]
Positive Response of Telehealth as Additional Option for Care in MS: Marisa McGinley, DOFebruary 28th 2023
The staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic discussed how patients with multiple sclerosis are more open to using telehealth for accessing their healthcare providers at the 2023 ACTRIMS Forum. [WATCH TIME: 4 minutes]
Rare Disease Day: Updates on Rett Syndrome and Pompe DiseaseFebruary 28th 2023
In recognition of Rare Disease Day, the NeurologyLive® team offered an extensive update on the state of care and treatment for a few rare neurological diseases, including Pompe disease, Rett syndrome, among others.
Building Trust and Increasing Patient Engagement With MS Communities: Marisa McGinley, DOFebruary 27th 2023
At the 2023 ACTRIMS Forum, the staff neurologist from the Mellen Center for MS Treatment and Research at the Cleveland Clinic talked about the lack of trust and engaging more with the MS community. [WATCH TIME: 5 minutes]
Access to MS Care in Underserved and Diverse Populations: Marisa McGinley, DOFebruary 26th 2023
The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke at the 2023 ACTRIMS Forum about disparities in care access for patients with MS. [WATCH TIME: 5 minutes]
Emerging Concepts in Multiple Sclerosis and Reversing Neurodegeneration: Daniel Ontaneda, MDFebruary 23rd 2023
The program committee vice-chair of ACTRIMS discussed the continued efforts to understand inflammation and neurodegeneration of multiple sclerosis. [WATCH TIME: 3 minutes]
NeuroVoices: Shazam Hussain, MD, FRCP, FAHA, on Weighing Direct to Angio Approaches for Mobile Stroke UnitsFebruary 22nd 2023
The director of Cleveland Clinic’s Cerebrovascular Center provided clinical perspective on the treatment decisions mobile stroke units face, and whether directly transferring patients to angiography suite is necessary.
Expanding the Window to Use Mechanical Thrombectomy, Treat Ischemic Stroke: Gabor Toth, MDFebruary 17th 2023
The vascular and interventional neurologist at Cleveland Clinic provided insight on a study presented at the 2023 International Stroke Conference that observed the clinical effectiveness of mechanical thrombectomy beyond 24 hours. [WATCH TIME: 6 minutes]
Advantages to Directly Transferring Stroke Treatment to Angiography: Shazam Hussain, MD, FRCP, FAHAFebruary 14th 2023
The director of Cleveland Clinic’s Cerebrovascular Center discussed the decisions mobile stroke units face and why opting for direct transfer to angiography is meant for certain scenarios. [WATCH TIME: 3 minutes]
Understanding Nuances of Mobile Stroke Units and When to Transfer Directly to Angiography: Shazam Hussain, MD, FRCP, FAHAFebruary 13th 2023
The director of Cleveland Clinic’s Cerebrovascular Center provided perspective on a new study presented at the International Stroke Conference on experiences of poststroke patients taken directly to angiography suite. [WATCH TIME: 3 minutes]
Direct Transfer to Angiography Following Mobile Stroke Unit Leads to Less Successful Recanalization, Increased MortalityFebruary 10th 2023
In comparison with those who underwent additional imaging, patients with large vessel occlusion who directly went to angiography suite had higher mortality, but with no difference in functional outcome.
NeuroVoices: Shumei Man, MD, on How Collaboration Between Hospitals Reduces Readmission for StrokeFebruary 8th 2023
The medical director of stroke at Fairview Hospital, an affiliate of Cleveland Clinic, provided perspective on a new intervention that improves communication and reduces hospital readmission for stroke.
Linking the Latest Research to Clinical Care in MS: Robert Bermel, MDDecember 19th 2022
The director of the Mellen Center for MS at Cleveland Clinic offered an overview of the State of the Science Summit that was held on November 10, 2022, featuring a panel of expert clinicians. [WATCH TIME: 4 minutes]
Chronic ASM Use Associated With Acute Symptomatic Seizures in Patients With StrokeDecember 6th 2022
Retrospective analysis of a group of individuals with stroke suggests that nonconvulsive acute symptomatic seizures are associated with long-term use of antiseizure medications, providing key data in guiding therapy use in this population.
NeuroVoices: Carrie Hersh, DO, MSc, on Applying 2-Stage Models to Improve Disease-Modifying Therapy Selection in MSNovember 30th 2022
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided background on incorporation of real-world methods to optimize treatment selection for multiple sclerosis.
Future Thoughts on Improving MS Trial Design, Calculations: Carrie Hersh, DO, MScNovember 23rd 2022
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided perspective on how the clinical community can improve trials for multiple sclerosis that help improve treatment decisions. [WATCH TIME: 4 minutes]
Expanding the Clinical Application of 2-Stage Models for Heterogenous Treatment Effects in MS: Carrie Hersh, DO, MScNovember 17th 2022
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine detailed the next steps in reforming and applying new 2-stage models that improve selection for MS disease-modifying therapies. [WATCH TIME: 6 minutes]
Establishing a Proof Of Concept Model to Improve MS Treatment Optimization: Carrie Hersh, DO, MScNovember 14th 2022
The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine offered insight on her presentation at ECTRIMS 2022 looking at 2-stage models to better understand heterogeneous treatment effects of MS DMTs. [WATCH TIME: 6 minutes]
Telehealth and Digital Measures May Assist With Monitoring MS Progression: Marisa McGinley, DONovember 7th 2022
The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke about her presentation from ECTRIMS 2022 on teleneurology and its utilization as a tool to make care more accessible to patients with MS. [WATCH TIME: 7 minutes]
Advocacy in Neurology: A Tool to Serve and Find FulfillmentNovember 7th 2022
Acting as an advocate is meaningful to neurologists because it speaks to their inner core—or their “why.” Neurologists have the agency to make this world a better place while working as a neurologist and an advocate at many levels.
Teleneurology Overcomes Health Disparities and Improves Accessibility in MS: Marisa McGinley, DONovember 6th 2022
The staff neurologist at the Mellen Center for MS Treatment and Research at Cleveland Clinic, spoke about her presentation on teleneurology being a beneficial healthcare tool for patients with MS at ECTRIMS 2022. [WATCH TIME: 7 minutes]
Ofatumumab’s Effect on Annualized Relapse Rate in Patients with MS: Jeffrey Cohen, MDOctober 28th 2022
The neurologist in the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic, shares more on his late breaker presentation from the 38th ECTRIMS conference. [WATCH TIME: 4 minutes]
Understanding the Utility of Specific Antibody Testing in Peripheral Neuropathies: Benjamin Claytor, MDOctober 18th 2022
The assistant professor of neurology at Cleveland Clinic provided insight on the differences in ganglioside vs paranodal antibodies and their clinical use in various neuropathies. [WATCH TIME: 3 minutes]
NurOwn Treatment Shows Positive Results in Phase 2 Study of Progressive Multiple SclerosisSeptember 16th 2022
Treatment with NurOwn resulted in response on several secondary outcomes, including timed 25-foot walk, 12-item multiple sclerosis walking scale, and low contrast letter acuity, among others.
NeuroVoices: Lynn Bekris, PhD, on Future Research for sTREM2, GFAP, and Immunotherapies in Alzheimer DiseaseSeptember 14th 2022
The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed the unanswered questions regarding biomarkers sTREM2 and GFAP, and the role they play in Alzheimer pathology.
Using Virtual Reality and Changes in Activities of Daily Living to Expose Prodromal Signs of Parkinson DiseaseSeptember 10th 2022
Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided commentary on an innovative approach using virtual reality to detect early signs of Parkinson disease.